POLE
ENSG00000177084
Target class
Enzyme
Chromosome
12
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Other names
- POLE1
- Target name
- POLE
- Gene name
- DNA polymerase epsilon, catalytic subunit
- Gene symbol
- POLE
- Protein name
- DNA polymerase epsilon catalytic subunit A (EC 2.7.7.7) (3'-5' exodeoxyribonuclease) (EC 3.1.11.-) (DNA polymerase II subunit A)
- Gene biotype
- Protein coding
- Gene family
- DNA polymerases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 76.88
- Tissue specificity (Gini)
- 0.464
- Tissue specificity (tau)
- 0.841
- KEGG gene identifiers
- hsa:5426
- Protein interaction confidence
- 0.869561
- Protein interaction partners
- 98
- R-HSA-110314
- R-HSA-5651801
- R-HSA-5656169
- R-HSA-5685942
- R-HSA-5696397
- R-HSA-5696400
- R-HSA-6782135
- R-HSA-6782210
- R-HSA-68952
- R-HSA-68962
- End position
- 132687376
- Start position
- 132623753
- Chromosome
- 12
- Strand
- Reverse
- Nucleus.
- Nucleoplasm
- Plasma membrane
- Tissue specificity (tau)
- 0.841407
- Expression inequality (Gini)
- 0.464418
Expression in transcripts per million
- Brain - Cerebellum
- 76.88
- Brain - Cerebellar Hemisphere
- 62.39
- Testis
- 50.2
- Spleen
- 33.32
- Cells - EBV-transformed lymphocytes
- 30.46
Expression in transcripts per million
- Brain - Cerebellum76.88
- Brain - Cerebellar Hemisphere62.39
- Testis50.2
- Spleen33.32
- Cells - EBV-transformed lymphocytes30.46
- Skin - Not Sun Exposed (Suprapubic)20.73
- Skin - Sun Exposed (Lower leg)20.51
- Ovary17.49
- Cervix - Endocervix17.16
- Uterus16.67
- Prostate16.59
- Cervix - Ectocervix16.5
- Fallopian Tube15.67
- Small Intestine - Terminal Ileum15.5
- Vagina14.78
- Nerve - Tibial14.55
- Esophagus - Gastroesophageal Junction14.34
- Bladder14.22
- Artery - Tibial13.82
- Esophagus - Muscularis13.42
- Colon - Sigmoid13.41
- Artery - Aorta13.19
- Colon - Transverse12.8
- Stomach12.14
- Breast - Mammary Tissue12.13
And 29 more, listed on the interactive page.
- GO:0000082
- GO:0000731
- GO:0006260
- GO:0006261
- GO:0006287
- GO:0006297
- GO:0005634
- GO:0005654
- GO:0005886
- GO:0008622
- GO:0003677
- GO:0003682
- GO:0003887
- GO:0005515
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor